SS-31 (Elamipretide): The First Approved Mitochondrial Drug — and What That Doesn't Mean

Common contexts

• Clinics may reference this peptide within broader wellness or longevity pathways.
• Use this directory page to compare profile transparency and consultation options.

Safety information

• This directory is informational and does not provide medical advice.
• Always discuss suitability and risk profile directly with a licensed clinician.

Clear intro

SS-31 is a landmark and a cautionary tale in one molecule: the first mitochondria-targeted drug ever approved — for a disease most people have never heard of — wrapped in a grey market selling it for aging, which is exactly what its trial record failed to support.

Who this is for

This page is for people researching mitochondrial and longevity peptides who want the precise boundary between what was approved in 2025 and what remains unproven, and for families researching Barth syndrome treatment.

What to ask before choosing a clinic

• FORZINITY is approved only for Barth syndrome — what evidence supports the use you're proposing for me?
• Elamipretide missed endpoints in heart failure and mitochondrial myopathy trials — how does that inform your recommendation?
• Is your product the licensed pharmaceutical, and if not, what exactly is in the vial?

Pricing and red flags

For anything other than Barth syndrome, no price is evidence-based. The question is not what SS-31 costs but why it is being offered for an indication its own trials could not support.

• Marketing the 2025 FDA approval as validation for longevity or energy uses — the approval is for one ultra-rare disease.
• Silence about the failed or stalled programmes in commoner conditions.
• Selling 'SS-31' vials while borrowing FORZINITY's regulatory credibility.

What is SS-31 (Elamipretide)?

SS-31 (elamipretide) is a four-amino-acid peptide designed to concentrate in mitochondria, where it binds cardiolipin — a phospholipid essential to the electron transport chain — and is intended to stabilise mitochondrial structure and improve energy production. After more than a decade of trials across heart failure, mitochondrial myopathy, eye disease, and rare genetic disorders, it earned a historic first: FDA accelerated approval in September 2025, under the brand name FORZINITY, for Barth syndrome — a life-limiting ultra-rare disease. It is the first approved drug that directly targets mitochondria. It is also, simultaneously, a staple of the grey-market longevity scene, where vials of 'SS-31' are sold for energy and anti-aging — uses for which no approval and no proven benefit exist.

How it works

Cardiolipin binding is a real, well-characterised mechanism, and Barth syndrome — caused by defective cardiolipin remodelling — is the indication where that mechanism most directly applies. That specificity cuts both ways: the disease where elamipretide won approval is precisely the one its mechanism fits best, and the broader indications where mitochondria decline with age — heart failure, myopathy — are where its trials repeatedly disappointed. Extrapolating from an ultra-rare-disease approval to general 'mitochondrial optimisation' inverts the actual evidence.

Cost overview

FORZINITY is a rare-disease pharmaceutical priced and supplied accordingly through specialist channels. Grey-market 'SS-31' vials are unregulated products whose price buys no verified identity, purity, or benefit. See the peptide therapy cost guide.

What to expect from clinics

• A credible provider should distinguish sharply between the Barth syndrome approval and everything else.
• Expect honesty that anti-aging and energy uses are unproven and unapproved — and that several large trials missed their endpoints.
• FORZINITY is a specialist rare-disease medicine; clinic-sold 'SS-31' is not FORZINITY.

Safety considerations

As FORZINITY, elamipretide's safety profile is characterised within its approved rare-disease context — administered under specialist supervision. Grey-market SS-31 carries the standard research-chemical risks: unverified identity, dose, and sterility, injected chronically for benefits no human trial has demonstrated. Accelerated approval also means confirmatory evidence is still being gathered even in Barth syndrome itself. This page does not recommend SS-31 and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.